Illumina (ILMN) Affirms Being 'Party H' in Complete Genomics' (GNOM) Filing
Tweet
Share
E-mailGet Alerts ILMN Hot Sheet
Join SI Premium – FREE
On November 16, 2012, Illumina, Inc. (Nasdaq: ILMN) confirmed that it is “Party H” as named in the Schedule 14D-9 (and related amendments) filed by Complete Genomics, Inc. (Nasdaq: GNOM) in connection with the tender offer by Beta Acquisition Corporation, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of BGI-Shenzhen, a company organized under the laws of the People’s Republic of China (together with Purchaser, “BGI”), to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics on the terms disclosed by Complete Genomics in its Schedule 14D-9 (and related amendments). Illumina’s most recent proposal, submitted on November 5, 2012, included the following terms:
* a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI;
* financed with cash-on-hand; and
* without any condition for further due diligence.
* a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI;
* financed with cash-on-hand; and
* without any condition for further due diligence.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real and RE/MAX Holdings receive court approval for merger
- Cytek faces $56M damages award in Beckman Coulter patent case
- Two Harbors receives final approval for CrossCountry Mortgage merger
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
